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Drawing on empirical research conducted in Argentina through the ESRC-funded ‘GET: Social Values Project’ (see 
http://www.law.ed.ac.uk/ahrc/esrcvaluesproject/), this Policy Brief (1) offers a very brief overview of the biotechnology research 
setting in Argentina, (2) provides evidence of stakeholder views on the need for research regulation in the regenerative medicine 
setting, (3) provides evidence of stakeholder views on the desired content for research regulation in the regenerative medicine setting, 
and (4) offers some general recommendations for policy in this field. 
 
BIOTECHNOLOGY IN ARGENTINA 
 
Despite suffering from many of the conditions which hinder innovation and 
population health in developing countries (ie: fragmented and under-funded 
healthcare systems, insufficient regulatory guidance, inadequate translational 
support), Argentina has signalled its intent in the biosciences field by: 
 
1. adopting the Buenos Aires Declaration, which explicitly enumerates 
biotechnology as a key developmental objective; 
 
2. forming the federal Ministry of Science, Technology and Productive 
Innovation, which has undertaken a variety of initiatives to stimulate 
research excellence, including the formation of the Advisory 
Commission on Regenerative Medicine and Cellular Therapies; 
 
3. making public research funds available so that it might better compete,1 
and 
 
4. promoting international networks and signing international agreements 
with specified groups to encourage scientific innovation and 
international cooperation.2 
 
 [Type a quote from the document or the summary of an interesting point. You can position HEALTH RESEARCH GOVERNANCE: 
ARGENTINE STAKEHOLDER OBJECTIVES 
Policy Brief 5:2010 
Shawn H.E. Harmon♠ 
♠ Principal Investigator, GET: Social Values Project; Research Fellow, InnoGen, ESRC Centre 
for Social and Economic Research on Innovation in Genomics, University of Edinburgh; 
Research Fellow in Law and Medical Technologies, SCRIPT, AHRC Research Centre in 
Intellectual Property and Technology Law, University of Edinburgh; Editor-in-Chief, 
SCRIPTed – A Journal of Law, Technology & Society; Member of the Nova Scotia Bar; BA, 
Saint Mary’s University (1993); LLB, University of New Brunswick (1996); LLM, University of 
Edinburgh (2004). 
1. The Argentine government remains the primary funding source for science, with the majority 
of research being performed in governmental institutions and universities: Ministerio de 
Ciencia y Tecnología de la República Argentina, Indicadores Ciencia Y Tecnologia: Argentina 
2006, available at The Argentine government remains the primary funding source for science, 
with the majority of research being performed in governmental institutions and universities: 
Ministerio de Ciencia y Tecnología de la República Argentina, Indicadores Ciencia Y 
Tecnologia: Argentina 2006, available at 
http://www.mincyt.gov.ar/indicadores_2006/publicacion/indicadores_2006.pdf [accessed 13 
January 2010]. [accessed 13 January 2010]. 
2. J. Niosi and S. Reid, “Biotechnology and Nanotechnology: Science-Based Enabling 
Technologies as Windows of Opportunity for LCDs” (2007) 35 World Development 426-438, 
N. Bar, “El Rating de la Ciencia”, La Nación, 13 May 2009, available at 
http://rcdtx.lanacion.com.ar/nota.asp?nota_id=1127536 [accessed 3 August 2009]. 
 
"As a 
consequence 
of the interest 
of the Minister 
of Science, I 
think this 
[stem cell 
research] is 
one of the 
things that is 
growing fast 
in the 
country.  Now 
we have, 
besides these 
ten projects, 
this cluster for 
stem 
cell research 
that involves 
nine different 
institutions in 
the country 
with 
fourteen 
different 
projects." 
 
 
 
 
  
"Science is 
moved by 
cost/effect . and 
law moves on 
the social effect. 
Science 
describes the 
world of being 
and the law the 
world of what 
must be." 
Indeed, Argentina has already established itself in the agro-biotech industry,1  
the animal research setting,4 and various support industries,5 and it has a long 
history of excellence in health-related research.6  Now, it appears to be targeting 
health biotechnology, and in particular stem cell research, as an arena in which to 
build comparative advantages.  For example, it is undertaking cutting edge 
research at the FLENI Institute, Hospital Garrahan, Leloir Institute, and others, 
and is engaged in the related field of bioinformatics, focusing on the use of 
information technologies in healthcare management.7  This is a very general 
history and current research context with which most of the respondents in the 
GET: Social Values Project were familiar. 
 
NEED FOR REGULATION 
 
Most respondents felt that internationally-informed standards for good science 
combined with rational boundaries and some oversight would be ideal for, and is 
needed in, Argentina.  For example, respondents stated as follows: 
 
I think that today, you need to regulate because the power and 
the possibilities … and the possible effects are so terrible that 
today, with a lot of care … and consulting specialists and 
[bioethicists], something must be done.  You can’t leave 
scientists to do what they want.  The risks are too much. 
 
I think they need to regulate scientific practice.  But very, very 
rational regulation.  The problem is that sometimes regulation is 
based on emotional questions and not really rational questions.  
But I think the people who are working [in] law need to be bold.  
I think we need a leash between science and law.  People with 
both information. 
 
In particular, it was felt that clear regulations are needed for the transition of 
work from basic research to the clinical setting: 
 
We are far from the clinic. …  I think that the translation from 
basic to clinic has to be a very regulated, exquisite regulated 
process.  There’s a lot of safety measures, peer review process, to 
be extremely well looked at. 
 
Yes, yes.  I think all the basic and clinical research in human 
beings have to be regulated by the Ministry of Science.  I 
understand the general research is one [but] you have different 
stages that [need regulation]. 
 
However, frustration was expressed at the perceived unlikelihood of achieving 
"The law has to 
intervene on 
some scientific 
contexts. . The 
law provides 
limits which 
cannot be 
provided by 
biology." 
3  It is the fourth largest producer of GM crops: see E. Trigo and E. Cap, “Ten Years of 
Genetically Modified Crops in Argentine Agriculture”, 2006, available at 
http://www.inta.gov.ar/ies/docs/otrosdoc/resyabst/ten_years.htm [accessed 4 August 2009], and 
W. Surman, “GM Crops in Argentina” (2007) New Agriculturalist, available at http://www.new-
ag.info/07/02/develop/dev2.php [accessed 4 August 2009]. 
4  D. Salamone et al., “High Level Expression of Bioactive Recombinant Human Growth 
Hormone in the Milk of a Cloned Transgenic Cow” (2006) 124 J Biotechnology 469-472. 
5  It manufactures materials for biofertilisers and is using bioplastics in the production of 
milk bottles: E. DaSilva, “Review: Biotechnology: Developing Countries and Globalization” (1998) 
14 World J Microbiology & Biotechnology 463-486, at 481-482. 
6  P. Kreimer and M. Lugones, “Rowing Against the Tide: Emergence and Consolidation of 
Molecular Biology in Argentina, 1960-90” (2002) 7 Science, Technology and Society 285-311. 
7  E. DaSilva, note 5 above, at 483. 
 
 
 
 
  
 
 
8  Returning to the social/science environment and the cell metaphor, 
unchecked science can easily go out of control and/or lose social utility, and might be 
seen as cancer. 
rational regulation in this setting, or of informed people (particularly scientists) 
actively shaping that regulation.  Respondents opined as follows: 
 
Yes, [we need a law] but [a] rational [law].  I am afraid because in 
the past when the government [adopts] legislation about 
science—well not really good. … 
 
It is very difficult to pass a logical law in [reproductive medicine] 
… which is a related field. … It is not only the Church, but also 
a lot of newspapers that are very controlling in the way they 
[present] abortion and [similar] topics. 
 
To be honest, I am so sceptical of the possibility of regulating 
stem cell research that I totally understand why some people 
would much rather say, ‘let’s not start anything’. 
 
Nonetheless, most respondents concluded that, regardless of the governmental 
course, scientists must form their own views about boundaries, should engage 
and network with other interested parties (eg: academics, bioethicists, etc.), and 
should encourage and take part in public discussions. 
 
CONTENT OF REGULATION 
 
On the issue of the content research (including clinical research) regulation, 
respondents in the GET: Social Values Project identified issues such as:  
 
1. clear and strict professional standards;  
2. training needs for IRBs;  
3. identification of values to guide research ;  
4. articulation of broad objectives for research;  
5. protections for research subjects and patients,  
6. oversight of research activities; and  
7. sanctions for unprofessional behaviour and breach of prohibitions. 
 
It was felt that known boundaries would have at least two salutary effects.  First, 
they would limit scientists by making clear what ends and/or methods are 
deemed to be (in)appropriate after existing methods and trajectories had been 
considered rationally (ie: it would reduce the possibilities of mavericks damaging 
the science/research reputation and agenda).8  Second, they would empower 
scientists in a positive way by assuring them that all of their activities within that 
articulated sphere are defensible and need not be sheltered from public scrutiny 
(ie: it would encourage the unveiling of science without putting scientists on the 
defensive). 
 
However, although almost all respondents felt that government boundary-setting 
would be valuable, there was no consensus on how that boundary-setting might 
be achieved, and they did not all agree that formal regulation was essential.  In 
this regard, opinions fell broadly into four camps: 
 
• Camp 1 – No Legislation: It is too early for legislation in the stem cell 
setting (R7).  Alternatively, legislation ought to be avoided because the 
"I think you 
have [to have] 
clear cut ideas 
or regulatory 
assistance, with 
a 
clear framework 
of what has to 
be done in this 
area: what type 
of cells you 
are going to 
work with; what 
area of 
methodology; or 
whatever.  And 
this is 
a double ethical 
need because 
there are public 
funds." 
 
 
 
 
 
 
 
 
 
tendency in Argentina is to ban and pass bad laws (R16).  It might be better 
for this area to first be overseen by a regulatory committee under the 
Ministry of Science or Health so some oversight and advice can be offered 
as the field develops, and any furore is avoided (R21). 
 
• Camp 2 – Specific Legislation: A stem cell-specific law is important because 
of the socially important issues thrown up by this research (R5, R10, R11, 
R14, R17, R19). 
 
• Camp 3 – General Research Legislation: Stem cell practices and issues are 
shared with other research and medical practices and techniques so a general 
medical research law is more useful, under which technique-specific 
regulations might be drafted by the executive on an as-needed basis (R1, R4, 
R6, R8, R18). 
 
• Camp 4 – General Medical Legislation: It is much more important to 
regulate the clinical setting than basic research; the safety of the patient is 
the most important element currently missing from the Argentine 
biomedical regulatory setting so it would be better to have a medical law 
(R3, R12, R15). 
 
In short, there was a plurality of opinions as to how the bioscience environment 
should respond and shape itself with respect to science boundary-setting, and there 
was a scepticism as to whether it could shake itself into action and set a course that 
engaged with this plurality (and other pluralities that might arise). 
 
RECOMMENDATIONS FOR ARGENTINA 
 
Given the plurality of opinions on how to proceed, the evidence generated by the 
GET: Social Values Project does not offer any firm basis for choosing a regulatory 
path.  However, it makes several key issues very clear, namely that most 
respondents: 
 
• desire rational boundary-setting for science in some form; 
 
• desire a regulatory framework that incorporates core values, including the 
value of knowledge and the freedom to work and the protection of 
individuals; 
 
• see a need for improved ethics education (within science) and science 
education (in the community); 
 
• desire improved spaces to network and discuss (and ultimately influence) 
policy debates relating to science trajectories and boundaries. 
 
Ultimately, the relationship (and particular power dynamic) between certain central 
actors (eg: the church, media and political elites) was viewed as creating a bottleneck, 
blocking other actors from a more active role within the social/science 
environment.  It was felt that this needs to be addressed if the rational regulation 
that is desired is to become a reality. 
 
 
"I think the 
elements [of 
good 
governance] 
would be to 
provide the 
good 
regulation. to 
communicate 
well, to 
stimulate 
research. to put 
initiatives 
[on the subject] 
on debate and 
get the subject 
to the public 
before it is a 
reality." 
 
 
 
 
 
This Policy Brief forms part of the programme of work of the 
“Governing Emerging Technologies: Social Values and Stem 
Cell Regulation in Argentina” project funded by the ESRC 
(Award No. RES-000-22-2678) and supported by 
AHRC/SCRIPT and InnoGen.   
For more on the GET: Social Values project, visit  
http://www.law.ed.ac.uk/ahrc/esrcvaluesproject/relatedproject 
